Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Preclinical Models: Innovative solutions to accelerate drug discovery and development
Bookmark and Share


Preclinical models are developed to test lead compounds for toxicity and efficacy. They are valuable tools for minimizing development costs and reducing failures prior to the commencement of human trials. Problems with traditional animal models such as cost, ethics and suitability have prompted researchers to develop new models and systems to overcome these disadvantages.

Scope of this research

  • Assessment of current developments in preclinical ADMET research for drug discovery and development.
  • Evaluation of the drivers behind innovation in preclinical research.
  • Details of current trends in ADMET research and how technology companies are developing models to improve and accelerate discovery and development.
  • Analysis of the in-vivo, in-vitro, in-silico and systems biology models that are advancing toxicity prediction in early drug discovery.
  • Key recommendations for industry players relating to the development of preclinical models to accelerate productivity and increase knowledge.

Research and analysis highlights

Established preclinical models correlate poorly with human in-vivo biological responses, and innovation is therefore needed to approximate human responses more accurately.

In-vivo, in-vitro and in-silico models are becoming increasingly more sophisticated, and a push for integration is creating demand for highly efficient centralized platforms to expedite predictive ADMET insight.

Pharmaceutical companies need more innovative preclinical solutions to advance drug discovery efforts, and in-silico biosimulation has the potential to transform the discovery and development process.

Key reasons to purchase this research

  • Understand the basis of ADMET testing and why it is a necessary and important component of preclinical research.
  • Evaluate the key recent developments and activities of companies who are developing and licensing new ADMET technologies.
  • Identify existing models and discover how new ones are being developed to improve productivity and knowledge.
  • Assess the technologies and systems that are driving drug discovery and development.
  • Examine action points and considerations for technology providers and pharmaceutical companies looking to accelerate preclinical research.


Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos